Ginkgo Bioworks' Autonomous Laboratory Driven by OpenAI's GPT-5 Achieves 40% Improvement Over State-of-the-Art Scientific Benchmark
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) and OpenAI report an autonomous laboratory using GPT-5 that cut cell-free protein synthesis reaction costs by 40% versus prior state of the art, producing sfGFP at $422 per gram versus $698 per gram. The system ran 36,000 reaction compositions across six iterative cycles and generated ~150,000 data points.
The collaborative workflow combined GPT-5 reasoning, Ginkgo's cloud laboratory infrastructure, validation via a Pydantic model, and limited human oversight; the AI-improved reagent mix is now commercially available.
Positive
- Reaction cost reduced by 40% to $422 per gram
- Executed 36,000 reaction compositions across six cycles
- Generated ~150,000 experimental data points
- Pydantic validation model to prevent invalid experiments
- AI-improved reagent mix now commercially available
Negative
- Human role still required for reagent preparation and oversight
- Results limited to stated experimental conditions and benchmark protein
- Commercialization scope and revenue impact not quantified
Key Figures
Market Reality Check
Peers on Argus
DNA was down 5.92% with modest volume, while several biotech peers like ANAB (-4.96%), XNCR (-4.32%), MGTX (-3.23%), KROS (-2.22%) and SEPN (-3.22%) also declined. However, the momentum scanner only flagged SVRA moving +4.29% with no news, so this setup looks more stock- and stock-cluster-specific than a clean, sector-wide AI/biotech rotation.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Aug 20 | AI lab partnership | Positive | -2.9% | Strategic AI-driven lab-in-the-loop workflow partnership for drug discovery. |
| Sep 18 | AI data platform launch | Positive | +8.8% | Launch of Ginkgo Datapoints to supply large biological datasets for AI training. |
| Apr 10 | AI grant award | Positive | -3.5% | Grant to develop AI-enabled forecasting tools for measles outbreaks. |
Past AI-related announcements for DNA have produced mixed reactions, with one strong positive move and two negative moves despite similar positive strategic themes around AI-enabled platforms and data services.
Recent history around Ginkgo’s AI initiatives shows recurring platform and data themes. On Apr 10, 2024, it received a grant for AI-enabled measles outbreak forecasting (-3.45% next day). On Sep 18, 2024, it launched Ginkgo Datapoints to support AI model training in biology with large, high-quality datasets (+8.81%). On Aug 20, 2025, it announced an AI-driven lab-in-the-loop drug discovery partnership with Inductive Bio and Tangible Scientific (-2.93%). Today’s GPT-5 autonomous lab update extends that AI-in-lab trajectory.
Historical Comparison
In the past 2 years, DNA has issued 3 AI-tagged releases with an average next-day move of 0.81%, showing that AI news has historically driven only modest price shifts overall.
AI-related news has progressed from an AI outbreak-forecasting grant to the Datapoints data platform and then to AI-driven lab-in-the-loop workflows, now extending into a GPT-5 powered autonomous laboratory executing tens of thousands of experiments.
Regulatory & Risk Context
DNA has an active Form S-3 shelf dated 2025-08-07 with at least one usage via a 424B5 on 2025-09-04, alongside an at-the-market program for up to $100,000,000 of Class A stock disclosed in an 8-K. These facilities provide flexibility to issue equity, which can introduce dilution if fully utilized.
Market Pulse Summary
This announcement highlights a GPT-5–powered autonomous lab that achieved a 40% reduction in cell-free protein synthesis costs, down to $422 per gram over 36,000 experiments and nearly 150,000 data points. It reinforces Ginkgo’s strategy of pairing AI with its cloud lab and RAC/Catalyst automation stack. In context with prior AI initiatives and existing ATM capacity, investors may watch how effectively this capability converts into recurring reagent sales and broader platform demand.
Key Terms
large language model technical
AI-generated analysis. Not financial advice.
- Research conducted in collaboration with OpenAI using Ginkgo's cloud laboratory
- Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis
- GPT-5-driven autonomous lab executed over 36,000 experiments
- Ginkgo now selling the AI-improved reaction mix in its reagents store, showing commercial potential of AI-driven science
The study represents a real-world scientific application of Ginkgo's autonomous lab. The collaborators combined OpenAI's GPT-5 reasoning model with Ginkgo's cloud laboratory infrastructure, built from its reconfigurable automation carts (RAC) technology and Catalyst automation software, to design, execute, and analyze experiments in an iterative, closed-loop workflow. GPT-5 was given internet access, a computer with data analysis packages, experimental (meta)data from prior iterations, and a preprint describing state of the art, and was able to operate like an experimental scientist – designing experiments, analyzing results, and refining its approach in response. In six rounds of experiments over the course of six months, it was able to design lower cost cell-free protein synthesis reaction compositions than had been shown in the scientific literature previously.
"By pairing a frontier large language model with an autonomous lab, we found reaction compositions that are notably cheaper than prior state of the art," said Reshma Shetty, co-founder of Ginkgo Bioworks and co-author of the study. "We expect more and more experiments to be run on autonomous labs where reagent and consumables costs dominate the cost of an experiment. Lower cost reagents for protein production enable more data generation and thus more scientific progress per dollar spent."
The autonomous lab achieved production of a standard benchmark protein, superfolder green fluorescent protein (sfGFP), at
"At OpenAI, this was the first time we were able to interface a frontier model with an autonomous lab to carry out experimentation at a very large scale," said Joy Jiao, life sciences research lead at OpenAI and co-corresponding author of the study. "This success points to how AI systems can augment the experimental workflow, contributing to hypothesis generation, testing, and refinement based on real-world data."
The autonomous lab executed more than 580 384-well plates, tested 36,000 reaction compositions, and generated nearly 150,000 experimental data points. Human involvement was primarily limited to reagent preparation, loading and unloading and system oversight, while experimental design, execution data interpretation, and hypothesis generation were handled by the GPT-5-driven autonomous lab. Notably, the model also proposed and prioritized new reagents to test, some of which independently anticipated findings from published research it had not been given access to.
To preclude the AI from proposing impractical, invalid, or hallucinatory experiments, every design was validated against a Pydantic model before execution, including checking plate layout, standards, controls, replication, reagent availability, and volume constraints. Only experiments that passed validation were eligible to run. Additional scoring prioritized scientific rigor and consideration of prior results. GPT-5 generated human-readable lab notebook entries documenting its analysis, observations, and rationale, providing transparency into its reasoning.
"This is AI doing real experimental science: designing experiments, running them, and learning from the results," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "AI combined with autonomous labs is needed to keep
The Pydantic model is being released open source and the AI-improved cell-free reaction mix can be ordered by the scientific community at https://reagents.ginkgo.bio/
About the Preprint
The findings are described in a scientific preprint that has not yet undergone peer review. The full manuscript, "Using a GPT-5-driven autonomous lab to optimize the cost and titer of cell-free protein synthesis," is available on OpenAI's website and will soon be available on bioRxiv.
About Ginkgo Bioworks
Ginkgo Bioworks builds the tools that make biology easier to engineer for everyone. The company offers autonomous laboratories that replace manual laboratory work with robotics in the lab, greatly improving the productivity of scientists. Ginkgo's in-house autonomous lab is also available as a "cloud lab" through our Datapoints and Solutions contract research services. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn.
Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of Ginkgo's autonomous laboratories. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the
Contacts
Ginkgo Bioworks investor contact:
investors@ginkgobioworks.com
Ginkgo Bioworks media contact:
press@ginkgobioworks.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-autonomous-laboratory-driven-by-openais-gpt-5-achieves-40-improvement-over-state-of-the-art-scientific-benchmark-302680619.html
SOURCE Ginkgo Bioworks
FAQ
What did Ginkgo (DNA) and OpenAI announce on February 5, 2026 about GPT-5 and autonomous labs?
How much did the GPT-5-driven autonomous lab reduce cell-free protein synthesis costs for DNA?
How extensive was the experimental scale used by Ginkgo and OpenAI in the DNA study?
What safeguards did Ginkgo use to prevent invalid experiments in the GPT-5 autonomous workflow?
Can researchers buy the AI-improved reagent mix from Ginkgo (DNA) and where is it available?
